Skip to content

Study · Case report or series · n = 1 · 2024

5 results

Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.

Patino J, Clearman AH, Miller L, Koenig MK

Clinical case reports24 Jun 2024Cited by 2 (Europe PMC)

PMID38919884 (opens in a new tab)PMCIDPMC11196835 (opens in a new tab)DOI10.1002/ccr3.9116 (opens in a new tab)PepBankPUB-38919884
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 17-year-old patient with membrane protein-associated neurodegeneration, elamipretide treatment was followed by symptomatic improvement in dysarthria.

    In plain wordsIn one teenage patient with a progressive brain disease, speech difficulty improved during elamipretide treatment.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseDysarthria symptom improvement
    Study

    n = 1

    Outcome group
    Overall treatment effect · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This case report presents a progressively declining 17-year-old patient with membrane protein-associated neurodegeneration who demonstrated symptomatic improvements in her dysarthria, dysphagia, and gait, and objective improvements in her 6-minute walk test and 5 times sit-to-stand test during elamipretide treatment.
    1 context sentence
    Title · context
    Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.
  2. 02HumanCase report or seriesEfficacy outcome

    In a 17-year-old patient with membrane protein-associated neurodegeneration, elamipretide treatment was followed by symptomatic improvement in dysphagia.

    In plain wordsIn one teenage patient with a progressive brain disease, swallowing difficulty improved during elamipretide treatment.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseDysphagia symptom improvement
    Study

    n = 1

    Outcome group
    Overall treatment effect · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This case report presents a progressively declining 17-year-old patient with membrane protein-associated neurodegeneration who demonstrated symptomatic improvements in her dysarthria, dysphagia, and gait, and objective improvements in her 6-minute walk test and 5 times sit-to-stand test during elamipretide treatment.
    1 context sentence
    Title · context
    Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.
  3. 03HumanCase report or seriesEfficacy outcome

    In a 17-year-old patient with membrane protein-associated neurodegeneration, elamipretide treatment was followed by symptomatic improvement in gait.

    In plain wordsIn one teenage patient with a progressive brain disease, walking improved during elamipretide treatment.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseGait symptom improvement
    Study

    n = 1

    Outcome group
    Overall treatment effect · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This case report presents a progressively declining 17-year-old patient with membrane protein-associated neurodegeneration who demonstrated symptomatic improvements in her dysarthria, dysphagia, and gait, and objective improvements in her 6-minute walk test and 5 times sit-to-stand test during elamipretide treatment.
    1 context sentence
    Title · context
    Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.
  4. 04HumanCase report or seriesEfficacy outcome

    In a 17-year-old patient with membrane protein-associated neurodegeneration, the 6-minute walk test improved during elamipretide treatment.

    In plain wordsIn one teenage patient with a progressive brain disease, walking test results improved during elamipretide treatment.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Increase6-minute walk test
    Study

    n = 1

    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This case report presents a progressively declining 17-year-old patient with membrane protein-associated neurodegeneration who demonstrated symptomatic improvements in her dysarthria, dysphagia, and gait, and objective improvements in her 6-minute walk test and 5 times sit-to-stand test during elamipretide treatment.
    1 context sentence
    Title · context
    Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.
  5. 05HumanCase report or seriesEfficacy outcome

    In a 17-year-old patient with membrane protein-associated neurodegeneration, the 5 times sit-to-stand test improved during elamipretide treatment.

    In plain wordsIn one teenage patient with a progressive brain disease, sit-to-stand test results improved during elamipretide treatment.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Increase5 times sit-to-stand test
    Study

    n = 1

    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This case report presents a progressively declining 17-year-old patient with membrane protein-associated neurodegeneration who demonstrated symptomatic improvements in her dysarthria, dysphagia, and gait, and objective improvements in her 6-minute walk test and 5 times sit-to-stand test during elamipretide treatment.
    1 context sentence
    Title · context
    Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.